These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 2954995)

  • 1. Regression analysis, proposed interpretative zone size standards, and quality control guidelines for a new macrolide antimicrobial agent, A-56268 (TE-031).
    Hanson CW; Bailer R; Gade E; Rode RA; Fernandes PB
    J Clin Microbiol; 1987 Jun; 25(6):1079-82. PubMed ID: 2954995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of interpretive criteria and quality control limits for macrolide and clindamycin susceptibility testing of Streptococcus pneumoniae.
    Jorgensen JH; Swenson JM; Tenover FC; Barry A; Ferraro MJ; Murray PR; Reller LB
    J Clin Microbiol; 1996 Nov; 34(11):2679-84. PubMed ID: 8897164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of in vitro spectra of activity of azithromycin, clarithromycin, and erythromycin tested against strains of Neisseria gonorrhoeae by reference agar dilution, disk diffusion, and Etest methods.
    Mehaffey PC; Putnam SD; Barrett MS; Jones RN
    J Clin Microbiol; 1996 Feb; 34(2):479-81. PubMed ID: 8789046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [In vitro antibacterial activity of clarithromycin, a new macrolide antibiotic, and regression curve].
    Soussy CJ; Le Van Thoi J; Cluzel M; Derlot E; Kitzis MD
    Pathol Biol (Paris); 1990 May; 38(5):401-6. PubMed ID: 2142274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimicrobial activity of coumermycin and recommendations for disk diffusion tests with 5- and 15-micrograms disks.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1987 May; 7(1):77-82. PubMed ID: 3691036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disk diffusion and disk elution tests with A-56268 and erythromycin.
    Barry AL; Jones RN; Thornsberry C
    Eur J Clin Microbiol; 1987 Feb; 6(1):109-11. PubMed ID: 2952500
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clarithromycin in vitro activity enhanced by its major metabolite, 14-hydroxyclarithromycin.
    Hoover WW; Barrett MS; Jones RN
    Diagn Microbiol Infect Dis; 1992; 15(3):259-66. PubMed ID: 1533827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antipneumococcal activity of telithromycin by agar dilution, microdilution, E test, and disk diffusion methodologies.
    Davies TA; Kelly LM; Jacobs MR; Appelbaum PC
    J Clin Microbiol; 2000 Apr; 38(4):1444-8. PubMed ID: 10747123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proposed changes in interpretive criteria and potency of ampicillin and ampicillin-sulbactam disks for susceptibility tests.
    Barry AL; Jones RN
    J Clin Microbiol; 1988 Apr; 26(4):750-4. PubMed ID: 3130390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial activity of SCH27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion/etest method evaluations and quality control guidelines. The Quality Control Study Group.
    Marshall SA; Jones RN; Erwin ME
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):19-25. PubMed ID: 9990471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.
    Fernandes PB; Bailer R; Swanson R; Hanson CW; McDonald E; Ramer N; Hardy D; Shipkowitz N; Bower RR; Gade E
    Antimicrob Agents Chemother; 1986 Dec; 30(6):865-73. PubMed ID: 2949695
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test.
    Barry AL; Fernandes PB; Jorgensen JH; Thornsberry C; Hardy DJ; Jones RN
    J Clin Microbiol; 1988 Nov; 26(11):2415-20. PubMed ID: 2976773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin. Collaborative Antimicrobial Susceptibility Testing Group.
    Barry AL; Thornsberry C; Gavan TL
    Eur J Clin Microbiol Infect Dis; 1989 Jun; 8(6):544-9. PubMed ID: 2548865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.
    Benson CA; Segreti J; Beaudette FE; Hines DW; Goodman LJ; Kaplan RL; Trenholme GM
    Antimicrob Agents Chemother; 1987 Feb; 31(2):328-30. PubMed ID: 2952063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [In vitro activity of roxithromycin against hospital bacteria and the concordance curve].
    Soussy CJ; Chanal M; Kitzis MD; Duval J; Cluzel R; Acar JF
    Pathol Biol (Paris); 1988 May; 36(5):420-4. PubMed ID: 2900488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965).
    Jones RN; Barry AL; Fuchs PC; Thornsberry C
    J Clin Microbiol; 1986 Aug; 24(2):233-9. PubMed ID: 3091634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An in-vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent.
    Anderson R; Joone G; van Rensburg CE
    J Antimicrob Chemother; 1988 Dec; 22(6):923-33. PubMed ID: 2977384
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimal dilution susceptibility testing conditions, recommendations for MIC interpretation, and quality control guidelines for the ampicillin-sulbactam combination.
    Jones RN; Barry AL
    J Clin Microbiol; 1987 Oct; 25(10):1920-5. PubMed ID: 3117843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MIC and time-kill study of antipneumococcal activities of RPR 106972 (a new oral streptogramin), RP 59500 (quinupristin-dalfopristin), pyostacine (RP 7293), penicillin G, cefotaxime, erythromycin, and clarithromycin against 10 penicillin-susceptible and -resistant pneumococci.
    Pankuch GA; Jacobs MR; Appelbaum PC
    Antimicrob Agents Chemother; 1996 Sep; 40(9):2071-4. PubMed ID: 8878583
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interpretive criteria for susceptibility testing of CI-960 (PD127391, AM-1091), fleroxacin, lomefloxacin, and temafloxacin against Neisseria gonorrhoeae, including drug stability in GC agar medium.
    Erwin ME; Jones RN
    J Clin Microbiol; 1992 May; 30(5):1170-3. PubMed ID: 1316366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.